Agios Pharmaceuticals Inc (AGIO): Lewis Clayton Jr. Cantley , director of Agios Pharmaceuticals Inc sold 2,504 shares on Jun 27, 2016. The Insider selling transaction was reported by the company on Jun 29, 2016 to the Securities and Exchange Commission. The shares were sold at $41.88 per share for a total value of $104,855.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 10, 2016, Scott Biller (Chief Scientific Officer) sold 27,500 shares at $65.00 per share price.On May 27, 2016, Lewis Clayton Jr. Cantley (director) sold 2,504 shares at $51.69 per share price.Also, On Dec 17, 2015, John Duncan Higgons (Chief Operating Officer) sold 20,000 shares at $50.09 per share price.On Oct 30, 2015, David P Schenkein (Chief Executive Officer) sold 4,000 shares at $80.26 per share price.
Shares of Agios Pharmaceuticals Inc (AGIO) ended Monday, Jun 27, 2016 session in red amid volatile trading. The shares closed down -4 points or -9.04% at $40.27 with 8,09,310 shares getting traded. Post opening the session at $43.69, the shares hit an intraday low of $39.84 and an intraday high of $44.26 and the price vacillated in this range throughout the day. The company has a market cap of $1,527 M and the number of outstanding shares has been calculated to be 3,79,21,791 shares. The 52-week high of Agios Pharmaceuticals Inc is $120.96 and the 52-week low is $33.5.
Company has been under the radar of several Street Analysts.Agios Pharmaceuticals Inc is Upgraded by JP Morgan to Overweight. Earlier the firm had a rating of Neutral on the company shares. The Rating was issued on Jun 13, 2016.Agios Pharmaceuticals Inc is Reiterated by SunTrust to Buy and the brokerage firm has raised the Price Target to $ 65 from a previous price target of $57 .The Rating was issued on May 18, 2016.Agios Pharmaceuticals Inc is Reiterated by Sun Trust Rbsn Humphrey to Buy and the brokerage firm has raised the Price Target to $ 65 from a previous price target of $57 .The Rating was issued on May 18, 2016.
Agios Pharmaceuticals Inc. (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells. Its products include AG-221 AG-120 and AG-348. Its lead product AG-348 in the RGD program is an orally available small molecule that targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. AG-221 is potent inhibitor of the mutated IDH2 protein being developed for the treatment hematological malignancies and advanced solid tumors. AG-120 is an orally available selective potent inhibitor of the mutated IDH1 protein being developed for the treatment hematological malignancies and advanced solid tumors.